Curaleaf and HEXO: The Only 2 Cannabis Stocks Every Investor Should Own

These two Canadian cannabis players are the only two I’d tap right now for a portfolio position for those inclined to gain exposure to this growth sector!

| More on:
Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The Canadian cannabis sector is on fire. Indeed, a return of approximately 300% for the sector since March lows is worth discussion. Year to date, this sector is up nearly 40%, with investors seeming to get excited about this growth sector once again.

I think we’re heading back into dangerous territory right now with respect to how these volatile stocks are trading. In particular, I think most Canadian cannabis players haven’t deserved the valuation bumps of late. The key catalyst taking this sector higher is speculation around the potential for U.S. legalization. However, most Canadian producers aren’t well positioned presently to take advantage of this significant development.

That said, I’ve picked two Canadian cannabis players I think are deserving of their recent stock price spikes.

Curaleaf

I’ve focused my attention on cannabis stocks almost exclusively to Curaleaf (TSXV:CURA) of late. This is because I view Curaleaf as the only Canada-listed cannabis producer well positioned to take advantage of the potential legalization of marijuana in the U.S.

Indeed, U.S. cannabis legalization is the biggest catalyst this sector has seen in a long time. The U.S. market is the crown jewel every company is chasing after right now. The thing is, Curaleaf is already operating in the U.S. in a big way. Furthermore, this company has done an incredible job of building out a vertically integrated business model that I think is the envy of most of its Canadian peers right now.

Curaleaf has built a solid presence in the U.S. on the foundation of an extremely well-designed business model. The company’s network of processing and cultivation facilities, value-added production facilities, and dispensaries make this company a force to be reckoned with. Indeed, when the competition comes to play, Curaleaf will be well prepared to engage in battle. For those willing to speculate on this sector and U.S. legalization in particular, this is the only company I’d pick to do so.

HEXO 

Another cannabis company I’ve highlighted in the past is HEXO (TSX:HEXO)(NYSE:HEXO). This is a company I’ve talked about for different reasons. Hexo is focused on developing regional supremacy in the Canadian market. I think Hexo has done an incredible job on gobbling up market share in Quebec, a key Canadian market. This is a company that has secured government contracts that are very lucrative, and are likely to continue long term. The Quebec government has shown an affinity for home-grown companies, and I don’t anticipate this will change any time soon.

Additionally, Hexo has a nice head start on its competition in the infused-beverage business. Right now, there’s an arms race going on with Canadian producer for “Cannabis 2.0” products. Hexo has done a good job of growing its market share in these important products. Long-term margin growth relies on the value-added products these companies can produce. Hexo is a solid domestic play and one I would consider as worthy of consideration for possible expansion south of the border when the time comes.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool recommends HEXO. and HEXO.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »